WINT — Windtree Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: John Tattory Resigns As Interim CFO of Windtree Therapeutics
Brief: Windtree Renews Agreement With Chang Gung University For Scientific Collaboration To Further SERCA2a Research
Brief: Windtree Eliminates $15 Million Contingent Liability To Deerfield Management Company
Brief: Windtree Therapeutics Got Letter From Nasdaq Notifying Closing Bid Price For Co's Common Stock Has Been Below Minimum Required For Continued Listing
Brief: Windtree Therapeutics Entered Amendment No. 1 To License Agreement With Philip Morris Products S.A.
Brief: Windtree Therapeutics Announces Reduction In Arrythmias In New Study With Istaroxime, Pure SERCA2a Activator
Brief: Windtree Therapeutics Q3 Net Income USD -4.425 Million
Brief: Windtree Announces Issuance Of Composition Of Matter Patent For Dual Mechanism Serca2a Activators By The Us Patent And Trademark Office
Windtree Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Windtree Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
Brief: Windtree Announces Notice Of Allowance From US Patent And Trademark Office
Brief: Windtree Therapeutics Files Preliminary Prospectus Related To Offer, Resale By Selling Stockholders Of Up To 236,836 Shares - SEC Filing
Brief: Windtree Therapeutics Reports First Quarter 2023 Financial Results And Provides Key Business Updates
Brief: Windtree Therapeutics Inc - QTRLY Loss Per Share $4.76
Brief: Windtree Therapeutics Announces Closing Of $12.42 Million Underwritten Public Offering Including Full Exercise Of Overallotment Option
Brief: Windtree Therapeutics Announces Pricing Of Upsized $10.8 Million Underwritten Public Offering
U.S. STOCKS ON THE MOVE-Western Alliance, WeWork, Baker Hughes
Windtree Therapeutics falls as chairman resigns
Brief: Windtree Therapeutics Chairman James Huang Steps Down